Dianthus Therapeutics announced Q1 2026 financial results and key business updates, including an early go decision in their Phase 3 CAPTIVATE trial for claseprubart in CIDP after achieving 20 responders early. The company is on track to start a Phase 3 trial for generalized Myasthenia Gravis mid-2026 and expects top-line results by late 2028. They also continue Phase 2 trials for Multifocal Motor Neuropathy and Phase 1 trials for DNTH212 targeting rheumatology diseases. Dianthus strengthened its cash position to approximately $1.2 billion after raising $719 million in a public offering, providing runway into 2030. These developments position Dianthus to advance its pipeline of next-generation autoimmune therapies.
Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) disclosed the sources and amounts of its distribution to be paid on May 29, 2026, including net investment income, capital gains, and return of capital. The fund follows a managed distribution poli...
Nature's Miracle Holding Inc. reported a net income of $2.85 million for Q1 2026, a significant turnaround from a $2.02 million loss in Q1 2025, driven by a $5 million gain on debt settlement. The company announced a strategic move to acquire a 55% s...
Westport Fuel Systems Inc. announced its 2026 Annual General and Special Meeting will be held virtually on June 30, 2026. Shareholders are encouraged to vote in advance using provided proxy forms to streamline the process. The company specializes in ...
HP Inc. reported second-quarter earnings of 86 cents per share, surpassing the consensus estimate of 71 cents by over 21%. Revenue also exceeded expectations, reaching $14.41 billion compared to the estimated $14.04 billion. The company saw strong gr...
Shareholders of Richmond Mutual Bancorporation and Farmers Bancorp have approved their merger, which will combine the two banks under the new name First Bank Midwest. Farmers Bancorp shareholders will receive 3.40 shares of Richmond Mutual stock for ...
